Considering the stability and easily manufactured nature of protein or peptidyl drugs, it may be more reasonable to develop antagonists of TSHR to avoid systemic side effects, while manifesting effectiveness to inhibit thyroid cancer growth. This evidence concerns the gene TSHR and thyroid cancer.